Literature DB >> 23582389

Is Option B+ the best choice?

Eric P Goosby.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23582389     DOI： 10.1016/S0140-6736(13)60832-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ('Option B+') in Malawi.

Authors:  Lyson Tenthani; Andreas D Haas; Olivia Keiser; Hannock Tweya; Andreas Jahn; Joep J van Oosterhout; Frank Chimbwandira; Zengani Chirwa; Wingston Ng'ambi; Alan Bakali; Sam Phiri; Landon Myer; Fabio Valeri; Marcel Zwahlen; Gilles Wandeler
Journal:  AIDS       Date:  2014-02-20       Impact factor: 4.177

2.  Improving PMTCT uptake and retention services through novel approaches in peer-based family-supported care in the clinic and community: a 3-arm cluster randomized trial (PURE Malawi).

Authors:  Nora E Rosenberg; Monique van Lettow; Hannock Tweya; Atupele Kapito-Tembo; Cassandre Man Bourdon; Fabian Cataldo; Levison Chiwaula; Veena Sampathkumar; Clement Trapence; Virginia Kayoyo; Florence Kasende; Blessings Kaunda; Colin Speight; Erik Schouten; Michael Eliya; Mina Hosseinipour; Sam Phiri
Journal:  J Acquir Immune Defic Syndr       Date:  2014-11-01       Impact factor: 3.731

3.  Messages on pregnancy and family planning that providers give women living with HIV in the context of a Positive Health, Dignity, and Prevention intervention in Mozambique.

Authors:  Starr Hilliard; Sarah A Gutin; Carol Dawson Rose
Journal:  Int J Womens Health       Date:  2014-12-12

4.  UNICEF's contribution to the adoption and implementation of option B+ for preventing mother-to-child transmission of HIV: a policy analysis.

Authors:  M F Chersich; E Newbatt; K Ng'oma; I de Zoysa
Journal:  Global Health       Date:  2018-06-01       Impact factor: 4.185
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.